Title |
Performance of Xpert® MTB/RIF among tuberculosis outpatients in Lilongwe, Malawi
|
---|---|
Published in |
African Journal of Laboratory Medicine, March 2017
|
DOI | 10.4102/ajlm.v6i2.464 |
Pubmed ID | |
Authors |
Tarsizio Chikaonda, Nelson Nguluwe, Brian Barnett, Runa H. Gokhale, Robert Krysiak, Isaac Thengolose, Nora E. Rosenberg, Christopher Stanley, James Mpunga, Irving F. Hoffman, Mina Hosseinipour, Lesley Scott, Wendy Stevens |
Abstract |
Xpert(®) MTB/RIF is a molecular test for the detection of Mycobacterium tuberculosis and rifampicin resistance. It is considered to be a great advance over smear microscopy and culture. However, there is very little information regarding the performance characteristics of Xpert MTB/RIF in Malawi. We aimed to evaluate the performance of Xpert MTB/RIF in a Malawian setting. Stored sputum pellets were processed on Xpert MTB/RIF between June 2012 and May 2014. Results were compared to mycobacteria growth indicator tube and Löwenstein-Jensen cultures, LED fluorescent microscopy and GenoType(®) MTBDRplus assay. Rifampicin resistance was confirmed by DNA sequencing. Of the 348 specimens with valid Xpert MTB/RIF results, 129/348 (37%) were smear-positive and 198/348 (57%) were culture-positive. Xpert MTB/RIF demonstrated a sensitivity of 93.8% (95% CI 89.4% - 96.8%) and specificity of 97.4% (95% CI 93.5% - 99.3%), with a positive predictive value of 97.8% (95% CI 94.6% - 99.4%) and a negative predictive value of 92.6% (95% CI 87.4% - 96.1%). Xpert MTB/RIF correctly identified 185/186 (99.5%) rifampicin-sensitive and 2/2 (100%) rifampicin-resistant M. tuberculosis strains. Mutations were not detected by sequencing in one isolate which was rifampicin resistant on Xpert MTB/RIF but sensitive on MTBDRplus. Four non-tuberculous mycobacteria grew from four smear-negative specimens, namely, M. avium (n = 1) and M. intracellulare (n = 3). No cross-reactivity was observed with any of the non-tuberculous mycobacteria when using Xpert MTB/RIF. When fully implemented, Xpert MTB/RIF may have an impact on patient care in Malawi. The increased diagnostic yield of Xpert MTB/RIF over smear microscopy can increase laboratory-confirmed tuberculosis detection and ensure that treatment is given to appropriate individuals or groups. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 29 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 17% |
Researcher | 4 | 14% |
Student > Doctoral Student | 3 | 10% |
Student > Ph. D. Student | 3 | 10% |
Other | 2 | 7% |
Other | 4 | 14% |
Unknown | 8 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 24% |
Immunology and Microbiology | 4 | 14% |
Nursing and Health Professions | 4 | 14% |
Agricultural and Biological Sciences | 3 | 10% |
Mathematics | 1 | 3% |
Other | 1 | 3% |
Unknown | 9 | 31% |